Fully integrated full service CRO providing services across the drug discovery & development pipeline.

Genesis Drug Discovery & Development (GD³) employs a range of advanced technologies aimed at enhancing drug discovery and development processes. Their proprietary platforms integrate cutting-edge methodologies in computational biology, high-throughput screening, and medicinal chemistry. These technologies enable GD³ to identify and optimize potential drug candidates efficiently, streamlining the transition from initial discovery to clinical development. The company emphasizes a data-driven approach, utilizing sophisticated algorithms and machine learning techniques to analyze biological data and predict the efficacy of drug compounds.

In addition to their computational capabilities, GD³ focuses on innovative therapeutic modalities, including small molecules and biologics. Their research leverages insights from genomics and proteomics to inform drug design, ensuring that their candidates are not only effective but also tailored to specific disease mechanisms. By combining these technologies with a robust understanding of pharmacology and toxicology, GD³ aims to accelerate the development of novel therapeutics that address unmet medical needs, ultimately improving patient outcomes.

United States

Genesis Drug Discovery and Development (GD3), a member of Genesis Global Group, is a contract research organization focused on providing services to support preclinical drug development programs from discovery to candidate selection. Our diversified portfolio of services covers all the areas of preclinical drug discovery/development including Discovery Biology, Chemistry, DMPK/in-vivo pharmacology and Toxicology. The portfolio spans a wide range of therapeutic areas include oncology, ocular, inflammation, metabolic diseases, ​and microbiome.

Genesis Drug Discovery & Development (GD³)

Company Details